Literature DB >> 12946997

Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.

Aihong Li1, Jianbiao Zhou, David Zuckerman, Montse Rue, Virginia Dalton, Cheryl Lyons, Lewis B Silverman, Stephen E Sallan, John G Gribben.   

Abstract

Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements provide clonal markers useful for diagnosis and measurement of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL). We analyzed the sequences of Ig and TCR gene rearrangements obtained at presentation and relapse in 41 children with ALL to study clonal stability, which has important implications for monitoring MRD, during the course of the disease. In 42%, all original Ig and/or TCR sequences were conserved. In 24%, one original sequence was preserved but the other lost, and in 14% the original sequences were conserved with new sequences identified at relapse. In 20% only new sequences were found at relapse. Using primers designed from the novel relapse sequences, the relapse clone could be identified as subdominant clones in the diagnostic sample in 8 of 14 patients. Alteration of these clonal gene rearrangements is a common feature in childhood ALL. MRD detection should include multiple gene targets to minimize false-negative samples or include also multicolor flow cytometry. In some cases the leukemic progenitor cell might arise earlier in lineage before DHJH recombination but retain the capacity to further differentiate into cells capable of altering the pattern of Ig and/or TCR rearrangements.

Entities:  

Mesh:

Year:  2003        PMID: 12946997     DOI: 10.1182/blood-2003-05-1455

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  X-linked clonality testing: interpretation and limitations.

Authors:  George L Chen; Josef T Prchal
Journal:  Blood       Date:  2007-04-13       Impact factor: 22.113

2.  Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

Authors:  Jianbiao Zhou; Meredith A Goldwasser; Aihong Li; Suzanne E Dahlberg; Donna Neuberg; Hongjun Wang; Virginia Dalton; Kathryn D McBride; Stephen E Sallan; Lewis B Silverman; John G Gribben
Journal:  Blood       Date:  2007-05-07       Impact factor: 22.113

3.  Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Authors:  Farhad Ravandi; Jeffrey L Jorgensen; Deborah A Thomas; Susan O'Brien; Rebecca Garris; Stefan Faderl; Xuelin Huang; Sijin Wen; Jan A Burger; Alessandra Ferrajoli; Partow Kebriaei; Richard E Champlin; Zeev Estrov; Pramoda Challagundla; Sa A Wang; Rajyalakshmi Luthra; Jorge E Cortes; Hagop M Kantarjian
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

4.  Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia.

Authors:  Charles Gawad; Francois Pepin; Victoria E H Carlton; Mark Klinger; Aaron C Logan; David B Miklos; Malek Faham; Gary Dahl; Norman Lacayo
Journal:  Blood       Date:  2012-08-28       Impact factor: 22.113

5.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

Authors:  Albert Moghrabi; Donna E Levy; Barbara Asselin; Ronald Barr; Luis Clavell; Craig Hurwitz; Yvan Samson; Marshall Schorin; Virginia K Dalton; Steven E Lipshultz; Donna S Neuberg; Richard D Gelber; Harvey J Cohen; Stephen E Sallan; Lewis B Silverman
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

6.  Evolution of Tumor Clones in Adult Acute Lymphoblastic Leukemia.

Authors:  S Yu Smirnova; Yu V Sidorova; N V Ryzhikova; K A Sychevskaya; E N Parovichnikova; A B Sudarikov
Journal:  Acta Naturae       Date:  2016 Oct-Dec       Impact factor: 1.845

7.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Malek Faham; Jianbiao Zheng; Martin Moorhead; Victoria E H Carlton; Patricia Stow; Elaine Coustan-Smith; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

8.  Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia.

Authors:  Alexander A Morley; Sue Latham; Michael J Brisco; Pamela J Sykes; Rosemary Sutton; Elizabeth Hughes; Vicki Wilczek; Bradley Budgen; Katrina van Zanten; Bryone J Kuss; Nicola C Venn; Murray D Norris; Catherine Crock; Colin Storey; Tamas Revesz; Keith Waters
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

9.  Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.

Authors:  Michael J Brisco; Sue Latham; Rosemary Sutton; Elizabeth Hughes; Vicki Wilczek; Katrina van Zanten; Bradley Budgen; Anita Y Bahar; Maria Malec; Pamela J Sykes; Bryone J Kuss; Keith Waters; Nicola C Venn; Jodie E Giles; Michelle Haber; Murray D Norris; Glenn M Marshall; Alexander A Morley
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

10.  Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.

Authors:  David Wu; Ryan O Emerson; Anna Sherwood; Mignon L Loh; Anne Angiolillo; Bryan Howie; Jennifer Vogt; Mark Rieder; Ilan Kirsch; Christopher Carlson; David Williamson; Brent L Wood; Harlan Robins
Journal:  Clin Cancer Res       Date:  2014-06-26       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.